Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care

被引:70
作者
Martin-Merino, Elisa [1 ]
Ruigomez, Ana [1 ]
Wallander, Mari-Ann [2 ]
Johansson, Saga [3 ,4 ]
Alberto Garcia-Rodriguez, Luis [1 ]
机构
[1] Ctr Espanol Invest Farmacoepidemiol, Madrid 28004, Spain
[2] Uppsala Univ, Dept Publ Hlth & Caring Sci, S-75183 Uppsala, Sweden
[3] AstraZeneca R&D, S-43183 Molndal, Sweden
[4] Sahlgrens Acad, Inst Med, SE-40530 Gothenburg, Sweden
关键词
Anxiety disorders; epidemiology; incidence; prevalence; primary health care; MENTAL-DISORDERS; DEPRESSION; EPIDEMIOLOGY; SYSTEMS; MOOD; RISK;
D O I
10.1093/fampra/cmp071
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Anxiety disorders are common and can cause substantial quality of life impairment. Objective. The aim of this study was to investigate the frequency of anxiety in UK primary care. Treatment patterns and factors associated with an anxiety diagnosis were also assessed. Methods. The Health Improvement Network was used to identify all patients aged 10-79 years with a new diagnosis of anxiety in 2002-04 (n = 40 873) and age-, sex- and calendar-year-matched controls (n = 50 000). A nested case-control analysis was used to quantify potential risk factors for anxiety by multivariate logistic regression. Results. The prevalence of anxiety was 7.2% and the incidence was 9.7 per 1000 person-years. Incidence and prevalence were highest in women and young adults (20-29 years). Anxiety was associated with heavy alcohol use, smoking and addiction problems as well as stress, sleep and depression disorders. Anxiety patients used health care services more frequently than controls. Among patients diagnosed with anxiety, 63% were treated pharmacologically. Antidepressants accounted for almost 80% of prescriptions. Conclusions. The prevalence and incidence of anxiety are high in UK primary care and are almost twice as high in women than in men. Anxiety is associated with other psychiatric morbidity as well as frequent health care use. Antidepressants are the most commonly used pharmacological treatment.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 30 条
[1]   The 12-month prevalence of DSM-IV anxiety disorders among Nigerian secondary school adolescents aged 13-18 years [J].
Adewuya, Abiodun O. ;
Ola, Bola A. ;
Adewumi, Tomi A. .
JOURNAL OF ADOLESCENCE, 2007, 30 (06) :1071-1076
[2]   High prevalence of mental disorders in primary care [J].
Ansseau, M ;
Dierick, M ;
Buntinkx, F ;
Cnockaert, P ;
De Smedt, J ;
Van Den Haute, M ;
Vander Mijnsbrugge, D .
JOURNAL OF AFFECTIVE DISORDERS, 2004, 78 (01) :49-55
[3]   Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology [J].
Baldwin, DS ;
Anderson, IM ;
Nutt, DJ ;
Bandelow, B ;
Bond, A ;
Davidson, JRT ;
den Boer, JA ;
Fineberg, NA ;
Knapp, M ;
Scott, J ;
Wittchen, HU .
JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) :567-596
[4]   Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life [J].
Beesdo, Katja ;
Bittner, Antje ;
Pine, Daniel S. ;
Stein, Murray B. ;
Hoefler, Michael ;
Lieb, Roselind ;
Wittchen, Hans-Ulrich .
ARCHIVES OF GENERAL PSYCHIATRY, 2007, 64 (08) :903-912
[5]   Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys [J].
Demyttenaere, K ;
Bruffaerts, R ;
Posada-Villa, J ;
Gasquet, I ;
Kovess, V ;
Lepine, JP ;
Angermeyer, MC ;
Bernert, S ;
de Girolamo, G ;
Morosini, P ;
Polidori, G ;
Kikkawa, T ;
Kawakami, N ;
Ono, Y ;
Takeshima, T ;
Uda, H ;
Karam, EG ;
Fayyad, JA ;
Karam, AN ;
Mneimneh, ZN ;
Medina-Mora, ME ;
Borges, G ;
Lara, C ;
de Graaf, R ;
Ormel, J ;
Gureje, O ;
Shen, YC ;
Huang, YQ ;
Zhang, MY ;
Alonso, J ;
Haro, JM ;
Vilagut, G ;
Bromet, EJ ;
Gluzman, S ;
Webb, C ;
Kessler, RC ;
Merikangas, KR ;
Anthony, JC ;
Von Korff, MR ;
Wang, PS ;
Alonso, J ;
Brugha, TS ;
Aguilar-Gaxiola, S ;
Lee, S ;
Heeringa, S ;
Pennell, BE ;
Zaslavsky, AM ;
Ustun, TB ;
Chatterji, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (21) :2581-2590
[6]   Size and burden of social phobia in Europe [J].
Fehm, L ;
Pelissolo, A ;
Furmark, T ;
Wittchen, HU .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (04) :453-462
[7]   The epidemiology of panic disorder and agoraphobia in Europe [J].
Goodwin, RD ;
Faravelli, C ;
Rosi, S ;
Cosci, F ;
Truglia, E ;
de Graaf, R ;
Wittchen, HU .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (04) :435-443
[8]  
Hirschfeld Robert M. A., 2001, Prim Care Companion J Clin Psychiatry, V3, P244
[9]   Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network [J].
Hubbard, R ;
Lewis, S ;
West, J ;
Smith, C ;
Godfrey, C ;
Smeeth, L ;
Farrington, P ;
Britton, J .
THORAX, 2005, 60 (10) :848-850
[10]  
Kadri Nadia, 2007, Ann Gen Psychiatry, V6, P6